Skip to content
Review Open access

CD97/ADGRE5 in Cancer: Structural Activation, Context-Dependent Signaling, and Therapeutic Targeting

Sep 2026 · Cells · Vol 15 · 0 citations · 93 references
Medicine

TL;DR

CD97 is an adhesion G-protein-coupled receptor encoded by ADGRE5 that integrates extracellular signals (including cell adhesion, ligand binding, and mechanical stimulation) with intracellular signal transduction and is involved in tumor stemness, invasion, metastasis, and cell survival through adhesion-related signaling, mechanosensing, and downstream pathway activation.

Abstract

Highlights What are the main findings? CD97 is involved in tumor stemness, invasion, metastasis, and cell survival through adhesion-related signaling, mechanosensing, and downstream pathway activation. CD97-targeted chimeric antigen receptor (CAR) therapies have shown antitumor activity in animal models, whereas CD97-targeted antibody–drug conjugates (ADCs) are currently supported by in vitro proof-of-concept evidence and RNA-mediated downregulation remains at an early exploratory stage. What are the implications of the main findings? High CD97 expression does not necessarily mean that a tumor will respond to CD97-targeted treatment. Patient selection should consider tumor dependence on CD97, normal-tissue expression, and potential on-target/off-tumor toxicity. Abstract CD97 is an adhesion G-protein-coupled receptor encoded by ADGRE5 that integrates extracellular signals (including cell adhesion, ligand binding, and mechanical stimulation) with intracellular signal transduction. Recent structural studies have further elucidated tethered/intramolecular agonist (TIA)/Stachel recognition and engagement of the seven-transmembrane domain (7TMD), activation-associated 7TMD conformational changes, and G-protein coupling, including the structural basis for the preferential coupling of CD97 to G13. Currently, antibody–drug conjugates (ADCs) targeting CD97 are supported by in vitro proof-of-concept evidence, whereas chimeric antigen receptor (CAR) strategies have shown antitumor activity in animal models of glioblastoma (GBM) and acute myeloid leukemia (AML). Existing research indicates that CD97 is involved in maintaining stem-like states, invasion and metastasis, metabolic adaptation, and stress survival in certain tumors, and its function varies depending on tumor type and cellular environment. Because CD97 is also expressed in normal immune cells and various nonhematopoietic tissues, systemic targeted therapy may be limited by on-target/off-tumor toxicity. This article reviews the latest advances in CD97 structure and signal transduction, and explores its tumor-related functions, biomarker value, evidence for ADC and CAR-related therapies, as well as early exploratory directions involving RNA-mediated downregulation and structure-guided interventions.

Read PDF

Similar papers

Review Open access Aug 2026

GPR65 in cancer: expression heterogeneity, invasion and metastasis, the tumor immune microenvironment, and translational implications.

This review summarizes current evidence on GPR65 in cancer from an immunopharmacological perspective, and discusses its molecular characteristics and proton-induced Gs-cAMP-PKA signaling, then examines tumor cell-intrinsic and immune-mediated functions, including acid-adaptive survival, macrophage polarization, CD8+ T-...

Fei Pan, Xielin Yan, Ye Chen et al. · 0 citations
Review Open access Sep 2026

Dysfunction of CD58 in tumor immune evasion: from mechanistic regulation to therapeutic resistance

CD58, the primary ligand of the co-stimulatory receptor CD2, plays a crucial role in the formation of the immunological synapse (IS) and the initiation of antitumor immunity involving T cells and natural killer (NK) cells. Aberrant CD58 expression, resulting from genomic inactivation, epigenetic silencing, transcript...

Peng-Fei Guo, Ming Yi, Yu-Jie Gan et al. · 0 citations
Review Open access Sep 2026

Research advances on CD47 in digestive system cancers: from molecular mechanisms to clinical translation

CD47 is a major innate immune checkpoint molecule that interacts with signal regulatory protein α (SIRPα) to deliver a “don’t eat me” signal and restrain macrophage-mediated phagocytosis. Accumulating evidence indicates that dysregulated CD47 expression is associated with immune escape, treatment resistance, and advers...

Hao-Lin Sun, Chen-Yu Wei, Jiang-Lan Long et al. · 0 citations
Review Open access Aug 2026

The PVR-TIGIT/CD96/CD226 axis: a novel immune checkpoint target in ovarian cancer

The structure, function, and receptor interactions of CD155 (PVR), with a particular focus on its immunoregulatory role in the ovarian tumor microenvironment are reviewed.

Ming-Yao Huang, Jia-Hui Zhang, Hui-Yan Huang et al. · 0 citations
Review Open access Aug 2026

The CD155-TIGIT Signaling Axis in NK Cell Immune Evasion in Tumors: Mechanisms, Synergy with TGF-β, and Combined Intervention Strategies

This review systematically integrates and finds that TGF-β not only directly suppresses NK cell function but also upregulates cluster of differentiation 155 (CD155) expression on tumor cells through both classical and non-classical pathways, able to amplify TIGIT-mediated negative signaling.

Shu-Yun Liu · 0 citations
Open access Aug 2026

IFI44L modulates chemoradiotherapy sensitivity and CD8+ T cell infiltration in colorectal cancer

By promoting CCL5-mediated CD8+ T cell recruitment, IFI44L links tumor-intrinsic molecular alterations with antitumor immune responses and may represent a potential biomarker or therapeutic target for improving CRT efficacy.

Linlin Zheng, Meng-Jie Li, Ruoqing Yan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.